The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.


The Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characterize and reduce the variability of standardized uptake values (SUVs). The Profile provides two complementary claims on the precision of SUV measurements. First, tumor glycolytic activity as reflected by the maximum SUV (SUVmax) is measurable from FDG PET/CT with a within-subject coefficient of variation of 10%-12%. Second, a measured increase in SUVmax of 39% or more, or a decrease of 28% or more, indicates that a true change has occurred with 95% confidence. Two applicable use cases are clinical trials and following individual patients in clinical practice. Other components of the Profile address the protocols and conformance standards considered necessary to achieve the performance claim. The Profile is intended for use by a broad audience; applications can range from discovery science through clinical trials to clinical practice. The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to outline future needs and potential developments.





Published Version (Please cite this version)


Publication Info

Kinahan, Paul E, Eric S Perlman, John J Sunderland, Rathan Subramaniam, Rathan Subramaniam, Scott D Wollenweber, Timothy G Turkington, Martin A Lodge, et al. (2020). The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. Radiology, 294(3). pp. 647–657. 10.1148/radiol.2019191882 Retrieved from

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Rathan Markandan Subramaniam

Adjunct Professor in the Department of Radiology

I am a Neuroradiologist and Nuclear Medicine physician with academic interest in cancer imaging, epigenetics, cancer care delivery, focused on head and neck cancer and a co-chair (imaging) of multi-institutional therapeutic clinical trials in head and neck cancer. 


Timothy Garvey Turkington

Associate Professor in Radiology

My work focuses on PET imaging physics, including instrumentation, reconstruction, and image processing.  We're working toward more quantitatively accurate PET,  reduction in scan times and radiation dose in PET/CT, novel imaging devices for PET (and SPECT), and application of PET to more clinical and research needs.  Positron Emission Tomography is now in widespread use as a clinical tool for oncology, neurology, and cardiology, and continues to be used as a research tool in these areas. 

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.